Rentschler Biopharma Introduces New Lentiviral Vector Manufacturing Toolbox

Rentschler Biopharma SE has launched an expanded service offering at its advanced therapies site in Stevenage, UK. This new initiative includes a lentiviral vector manufacturing (LVV) toolbox integrated with existing adeno-associated viral (AAV) vector services. This expansion is set to support the increasing demand for advanced therapy medicinal products (ATMPs).

Lentiviral vectors are critical in gene transfer applications, helping to treat genetic diseases like beta-thalassemia and modifying T-cells for cancer immunity. The new LVV manufacturing capabilities position Rentschler Biopharma to meet the growing market needs for gene modulation and cell therapies.

Chief Operating Officer Christiane Bardroff remarked that this development is part of the company's strategy to advance medicine and improve patients' lives. The Stevenage facility offers customized solutions, proprietary HEK293 cell lines, and cost-saving advantages, further solidifying Rentschler Biopharma as a reliable partner in the biopharmaceutical sector.

General Manager Robert Panting emphasized the importance of the new toolbox in advancing clients' viral vector programs from pre-clinical stages to market release, enhancing the company's role within the global advanced therapies sector.